← ANALYST RATINGS · TIPRANKS
Inventiva (IVA): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $15.50, the highest $26.00, the lowest $10.00. The average is +427.2% from the last price of $2.94.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 | Sell | +2.0% | Downgrade | 16.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $12.00 | Buy | +308.2% | Reiterated | 30.09.26on TipRanks 07:50 | +12.4%next day −6.4% · 5 days −10.7% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $12.00 | Buy | +308.2% | Reiterated | 29.09.26on TipRanks Sep 30 04:50 | −6.6%next day +12.4% · 5 days +3.2% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 29.09.26on TipRanks 08:11 | −6.6%next day +12.4% · 5 days +3.2% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $20.00 → $21.00+5.0% | Buy | +614.3% | Reiterated | 29.09.26on TipRanks 07:20 | −6.6%next day +12.4% · 5 days +3.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +19.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $14.00 | Buy | +376.2% | Reiterated | 28.09.26on TipRanks Sep 29 06:50 | +5.5%next day −6.6% · 5 days −2.6% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $10.00 | Buy | +240.1% | Reiterated | 28.09.26on TipRanks Sep 29 01:00 | +5.5%next day −6.6% · 5 days −2.6% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $14.00 | Buy | +376.2% | Reiterated | 28.09.26on TipRanks 11:15 | +5.5%next day −6.6% · 5 days −2.6% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $15.00 | Buy | +410.2% | Reiterated | 23.09.26on TipRanks 06:50 | −4.8%next day −5.4% · 5 days +7.6% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $26.00 | Buy | +784.4% | Reiterated | 16.09.26on TipRanks Sep 17 04:25 | −1.4%next day −2.2% · 5 days −11.0% | ↗ |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Initiated | 17.07.26on TipRanks 07:47 | +3.2%next day −4.3% · 5 days −2.9% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $18.00 | Buy | +512.2% | Reiterated | 04.06.26on TipRanks 04:35 | +4.3%next day −2.1% · 5 days −7.6% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $24.00 | Buy | +716.3% | Reiterated | 28.01.26on TipRanks 06:25 | −0.6%next day −7.3% · 5 days −11.6% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $13.00 | Buy | +342.2% | Initiated | 05.11.25on TipRanks 16:40 | +3.0%next day −4.2% · 5 days −8.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Inventiva
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.50 at a price of $3.69 (+320.1%); now: $15.50 at $2.94 (+427.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 8 | 7 | 13 | 10 |
| Buy | 2 | 2 | 3 | 2 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 31.03.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.33 (from $-0.44 to $-0.24). Last quarter: $-0.20.
Sales
Next quarter’s sales estimate — $5M (from $0M to $11M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Inventiva
- CEO: Andrew Obenshain
- Employees: 77
- 50 rue de Dijon, Daix, BF, 21121, FR
- www.inventivapharma.com
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Data from the stock’s TipRanks forecast page, read 75 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗